Skip to main content

Advertisement

SpringerLink
Log in

Regulation and action of interferon-stimulated gene 15 in breast cancer cells

  • Review Article
  • Published:
Human Cell Aims and scope Submit manuscript

Abstract

Interferon-stimulated gene 15 (ISG15) is a critical ubiquitin-like protein that can be conjugated to proteins via the ISGylation system to modify them posttranslationally. Furthermore, ISG15 can be detected as non-conjugated or free, intracellularly and/or extracellularly. Both conjugated and free ISG15 participate in different cancer types, including breast cancer. Here, we highlighted the findings on ISG15 and protein ISGylation, and their implications in the field of breast cancer research. ISG15 emerges as a central element in mammary tumors and may become a crucial protein in the strategies for detection, prognosis, and therapy of breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

    Article  PubMed  Google Scholar 

  2. Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941–53.

    Article  CAS  PubMed  Google Scholar 

  3. Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. 2018. https://gco.iarc.fr/today. Accessed 20 July 2020

  4. Aleskandarany MA, Abduljabbar R, Ashankyty I, et al. Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis. Breast Cancer Res Treat. 2016;159:215–27.

    Article  CAS  PubMed  Google Scholar 

  5. Turashvili G, Brogi E. Tumor heterogeneity in breast cancer. Front Med. 2017;4:227.

    Article  Google Scholar 

  6. Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24:2206–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Tsang JYS, Tse GM. Molecular classification of breast cancer. Adv Anat Pathol. 2020;27:27–35.

    Article  CAS  PubMed  Google Scholar 

  8. Bertucci F, Chaffanet M, Birnbaum D. An ICGC major achievement in breast cancer: a comprehensive catalog of mutations and mutational signatures. Chin Clin Oncol. 2017;6:4.

    Article  PubMed  Google Scholar 

  9. Dai X, Xiang L, Li T, Bai Z. Cancer hallmarks, biomarkers and breast cancer molecular subtypes. J Cancer. 2016;7:1281–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Knight E Jr, Fahey D, Cordova B, et al. A 15-kDa interferon-induced protein is derived by COOH-terminal processing of a 17-kDa precursor. J Biol Chem. 1988;263:4520–2.

    CAS  PubMed  Google Scholar 

  11. Potter JL, Narasimhan J, Mende-Mueller L, Haas AL. Precursor processing of pro-ISG15/UCRP, an interferon-beta-induced ubiquitin-like protein. J Biol Chem. 1999;274:25061–8.

    Article  CAS  PubMed  Google Scholar 

  12. Reich N, Evans B, Levy D, Fahey D, Knight E Jr, Darnell JE Jr. Interferon-induced transcription of a gene encoding a 15-kDa protein depends on an upstream enhancer element. Proc Natl Acad Sci USA. 1987;84:6394–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Loeb KR, Haas AL. The interferon-inducible 15-kDa ubiquitin homolog conjugates to intracellular proteins. J Biol Chem. 1992;267:7806–13.

    CAS  PubMed  Google Scholar 

  14. Malakhov MP, Kim KI, Malakhova OA, Jacobs BS, Borden EC, Zhang DE. High-throughput immunoblotting. Ubiquitiin-like protein ISG15 modifies key regulators of signal transduction. J Biol Chem. 2003;278:16608–13.

    Article  CAS  PubMed  Google Scholar 

  15. Narasimhan J, Wang M, Fu Z, Klein JM, Haas AL, Kim JJ. Crystal structure of the interferon-induced ubiquitin-like protein ISG15. J Biol Chem. 2005;280:27356–65.

    Article  CAS  PubMed  Google Scholar 

  16. Dastur A, Beaudenon S, Kelley M, Krug RM, Huibregtse JM. Herc5, an interferon-induced HECT E3 enzyme, is required for conjugation of ISG15 in human cells. J Biol Chem. 2006;281:4334–8.

    Article  CAS  PubMed  Google Scholar 

  17. Kim KI, Giannakopoulos NV, Virgin HW, Zhang DE. Interferon-inducible ubiquitin E2, Ubc8, is a conjugating enzyme for protein ISGylation. Mol Cell Biol. 2004;24:9592–600.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Malakhova OA, Yan M, Malakhov MP, et al. Protein ISGylation modulates the JAK-STAT signaling pathway. Genes Dev. 2003;17:455–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Park JH, Yang SW, Park JM, et al. Positive feedback regulation of p53 transactivity by DNA damage-induced ISG15 modification. Nat Commun. 2016;7:12513.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Park JM, Yang SW, Yu KR, et al. Modification of PCNA by ISG15 plays a crucial role in termination of error-prone translesion DNA synthesis. Mol Cell. 2014;54:626–38.

    Article  CAS  PubMed  Google Scholar 

  21. Wong JJ, Pung YF, Sze NS, Chin KC. HERC5 is an IFN-induced HECT-type E3 protein ligase that mediates type I IFN-induced ISGylation of protein targets. Proc Natl Acad Sci USA. 2006;103:10735–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Zhao C, Beaudenon SL, Kelley ML, et al. The UbcH8 ubiquitin E2 enzyme is also the E2 enzyme for ISG15, an IFN-alpha/beta-induced ubiquitin-like protein. Proc Natl Acad Sci USA. 2004;101:7578–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Zou W, Wang J, Zhang DE. Negative regulation of ISG15 E3 ligase EFP through its autoISGylation. Biochem Biophys Res Commun. 2007;354:321–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Zou W, Zhang DE. The interferon-inducible ubiquitin-protein isopeptide ligase (E3) EFP also functions as an ISG15 E3 ligase. J Biol Chem. 2006;281:3989–94.

    Article  CAS  PubMed  Google Scholar 

  25. Oudshoorn D, van Boheemen S, Sanchez-Aparicio MT, Rajsbaum R, Garcia-Sastre A, Versteeg GA. HERC6 is the main E3 ligase for global ISG15 conjugation in mouse cells. PLoS ONE. 2012;7:e29870.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Takeuchi T, Inoue S, Yokosawa H. Identification and Herc5-mediated ISGylation of novel target proteins. Biochem Biophys Res Commun. 2006;348:473–7.

    Article  CAS  PubMed  Google Scholar 

  27. Basters A, Geurink PP, El Oualid F, et al. Molecular characterization of ubiquitin-specific protease 18 reveals substrate specificity for interferon-stimulated gene 15. FEBS J. 2014;281:1918–28.

    Article  CAS  PubMed  Google Scholar 

  28. Huang YF, Bulavin DV. Oncogene-mediated regulation of p53 ISGylation and functions. Oncotarget. 2014;5:5808–18.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Im E, Yoo L, Hyun M, Shin WH, Chung KC. Covalent ISG15 conjugation positively regulates the ubiquitin E3 ligase activity of parkin. Open Biol. 2016;6:160193.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  30. Jeon YJ, Choi JS, Lee JY, et al. ISG15 modification of filamin B negatively regulates the type I interferon-induced JNK signalling pathway. EMBO Rep. 2009;10:374–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Lee JH, Bae JA, Lee JH, et al. Glycoprotein 90K, downregulated in advanced colorectal cancer tissues, interacts with CD9/CD82 and suppresses the Wnt/beta-catenin signal via ISGylation of beta-catenin. Gut. 2010;59:907–17.

    Article  CAS  PubMed  Google Scholar 

  32. Xu D, Zhang T, Xiao J, et al. Modification of BECN1 by ISG15 plays a crucial role in autophagy regulation by type I IFN/interferon. Autophagy. 2015;11:617–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Swaim CD, Scott AF, Canadeo LA, Huibregtse JM. Extracellular ISG15 signals cytokine secretion through the LFA-1 integrin receptor. Mol Cell. 2017;68(581–90):e5.

    Google Scholar 

  34. Tecalco Cruz AC, Mejia-Barreto K. Cell type-dependent regulation of free ISG15 levels and ISGylation. J Cell Commun Signal. 2017;11:127–35.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Tecalco-Cruz AC, Cruz-Ramos E. Protein ISGylation and free ISG15 levels are increased by interferon gamma in breast cancer cells. Biochem Biophys Res Commun. 2018;499:973–8.

    Article  CAS  PubMed  Google Scholar 

  36. Mojic M, Takeda K, Hayakawa Y. The dark side of IFN-gamma: its role in promoting cancer immunoevasion. Int J Mol Sci. 2017;19:89.

    Article  PubMed Central  CAS  Google Scholar 

  37. Gooch JL, Herrera RE, Yee D. The role of p21 in interferon gamma-mediated growth inhibition of human breast cancer cells. Cell Growth Differ. 2000;11:335–42.

    CAS  PubMed  Google Scholar 

  38. Niu XL, Wang Y, Yao Z, et al. Autocrine interferon-gamma may affect malignant behavior and sensitivity to tamoxifen of MCF-7 via estrogen receptor beta subtype. Oncol Rep. 2015;34:3120–30.

    Article  CAS  PubMed  Google Scholar 

  39. Cui XF, Imaizumi T, Yoshida H, Borden EC, Satoh K. Retinoic acid-inducible gene-I is induced by interferon-gamma and regulates the expression of interferon-gamma stimulated gene 15 in MCF-7 cells. Biochem Cell Biol. 2004;82:401–5.

    Article  CAS  PubMed  Google Scholar 

  40. Tecalco-Cruz AC, Cortes-Gonzalez CC, Cruz-Ramos E, Ramirez Jarquin JO, Romero-Mandujano AK, Sosa-Garrocho M. Interplay between interferon-stimulated gene 15/ISGylation and interferon gamma signaling in breast cancer cells. Cell Signal. 2019;54:91–101.

    Article  CAS  PubMed  Google Scholar 

  41. Cruz-Ramos E, Macias-Silva M, Sandoval-Hernandez A, Tecalco-Cruz AC. Non-muscle myosin IIA is post-translationally modified by interferon-stimulated gene 15 in breast cancer cells. Int J Biochem Cell Biol. 2019;107:14–26.

    Article  CAS  PubMed  Google Scholar 

  42. Ning Y, Riggins RB, Mulla JE, Chung H, Zwart A, Clarke R. IFNgamma restores breast cancer sensitivity to fulvestrant by regulating STAT1, IFN regulatory factor 1, NF-kappaB, BCL2 family members, and signaling to caspase-dependent apoptosis. Mol Cancer Ther. 2010;9:1274–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Thakkar SG, Peereboom D, Olencki T, et al. Short communication: phase I clinical and gene modulatory evaluation of tamoxifen and IFN-alpha2b. J Interferon Cytokine Res. 2006;26:800–3.

    Article  CAS  PubMed  Google Scholar 

  44. Legrier ME, Bieche I, Gaston J, et al. Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer. Br J Cancer. 2016;114:177–87.

    Article  CAS  PubMed  Google Scholar 

  45. Weichselbaum RR, Ishwaran H, Yoon T, et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci USA. 2008;105:18490–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Giannakopoulos NV, Luo JK, Papov V, et al. Proteomic identification of proteins conjugated to ISG15 in mouse and human cells. Biochem Biophys Res Commun. 2005;336:496–506.

    Article  CAS  PubMed  Google Scholar 

  47. Dulyaninova NG, House RP, Betapudi V, Bresnick AR. Myosin-IIA heavy-chain phosphorylation regulates the motility of MDA-MB-231 carcinoma cells. Mol Biol Cell. 2007;18:3144–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Cerikan B, Schiebel E. DOCK6 inactivation highlights ISGylation as RHO-GTPase balancer. Cell Cycle. 2017;16:304–5.

    Article  CAS  PubMed  Google Scholar 

  49. Burks J, Reed RE, Desai SD. ISGylation governs the oncogenic function of Ki-Ras in breast cancer. Oncogene. 2014;33:794–803.

    Article  CAS  PubMed  Google Scholar 

  50. Zhang H, Angelopoulos N, Xu Y, et al. Proteomic profile of KSR1-regulated signalling in response to genotoxic agents in breast cancer. Breast Cancer Res Treat. 2015;151:555–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Englert NA, Spink BC, Spink DC. Persistent and non-persistent changes in gene expression result from long-term estrogen exposure of MCF-7 breast cancer cells. J Steroid Biochem Molr Biol. 2011;123:140–50.

    Article  CAS  Google Scholar 

  52. Forys JT, Kuzmicki CE, Saporita AJ, Winkeler CL, Maggi LB Jr, Weber JD. ARF and p53 coordinate tumor suppression of an oncogenic IFN-beta-STAT1-ISG15 signaling axis. Cell Rep. 2014;7:514–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Hermann MR, Jakobson M, Colo GP, et al. Integrins synergise to induce expression of the MRTF-A-SRF target gene ISG15 for promoting cancer cell invasion. J Cell Sci. 2016;129:1391–403.

    Article  CAS  PubMed  Google Scholar 

  54. Desai SD, Reed RE, Burks J, et al. ISG15 disrupts cytoskeletal architecture and promotes motility in human breast cancer cells. Exp Biol Med. 2012;237:38–49.

    Article  CAS  Google Scholar 

  55. Kiessling A, Hogrefe C, Erb S, et al. Expression, regulation and function of the ISGylation system in prostate cancer. Oncogene. 2009;28:2606–20.

    Article  CAS  PubMed  Google Scholar 

  56. Burks J, Reed RE, Desai SD. Free ISG15 triggers an antitumor immune response against breast cancer: a new perspective. Oncotarget. 2015;6:7221–31.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Bektas N, Noetzel E, Veeck J, et al. The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer. Breast Cancer Res. 2008;10:R58.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  58. Rojas LK, Trilla-Fuertes L, Gamez-Pozo A, et al. Proteomics characterisation of central nervous system metastasis biomarkers in triple negative breast cancer. Ecancermedicalscience. 2019;13:891.

    Article  Google Scholar 

  59. Li Y, Bai W, Zhang L. The overexpression of CD80 and ISG15 are associated with the progression and metastasis of breast cancer by a meta-analysis integrating three microarray datasets. Pathol Oncol Res. 2020;26:443–52.

    Article  CAS  PubMed  Google Scholar 

  60. Lo PK, Yao Y, Lee JS, et al. LIPG signaling promotes tumor initiation and metastasis of human basal-like triple-negative breast cancer. eLife. 2018;7:e31334.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Tesauro C, Simonsen AK, Andersen MB, et al. Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study. BMC Cancer. 2019;19:1158.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Desai SD, Wood LM, Tsai YC, et al. ISG15 as a novel tumor biomarker for drug sensitivity. Mol Cancer Ther. 2008;7:1430–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Jeon YJ, Jo MG, Yoo HM, et al. Chemosensitivity is controlled by p63 modification with ubiquitin-like protein ISG15. J Clin Investig. 2012;122:2622–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Wood LM, Pan ZK, Seavey MM, Muthukumaran G, Paterson Y. The ubiquitin-like protein, ISG15, is a novel tumor-associated antigen for cancer immunotherapy. Cancer Immunol Immunother. 2012;61:689–700.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Programa en Ciencias Genómicas, Universidad Autónoma de La Ciudad de México (UACM), Apdo, 03100, Mexico City, Mexico

    Angeles C. Tecalco-Cruz & Eduardo Cruz-Ramos

  2. Instituto de Fisiología Celular, Universidad Nacional Autónoma de México (UNAM), Apdo, 04510, Mexico City, Mexico

    Josué O. Ramírez-Jarquín

Authors
  1. Angeles C. Tecalco-Cruz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Josué O. Ramírez-Jarquín
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eduardo Cruz-Ramos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Angeles C. Tecalco-Cruz.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tecalco-Cruz, A.C., Ramírez-Jarquín, J.O. & Cruz-Ramos, E. Regulation and action of interferon-stimulated gene 15 in breast cancer cells. Human Cell 33, 954–962 (2020). https://doi.org/10.1007/s13577-020-00414-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13577-020-00414-x

Keywords

Search

Navigation